SCHEMBL5143809

SCHEMBL5143809

CCCCNC(=O)COc1ccc2c(c1)CC(N(Cc1ccccc1)C[C@H](O)COc1ccc3[nH]ccc3c1)CCC2

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CTSD P07339 8/20 0.38
HTR1D P28221 1/20 0.38
HTR1B P28222 1/20 0.38
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
TSHR P16473 1/20 0.36
RECQL P46063 1/20 0.36
PPARD Q03181 1/20 0.36
HDAC8 Q9BY41 2/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5143801 0.89 TAOK1 (0.45) CTSDPRMT5WDR77TSHRRECQL
SCHEMBL5145299 0.83 PRMT5 (0.44) PRMT5WDR77TSHRRECQLMEN1
Hydrochloric Acid SCHEMBL5143605 0.82 ADRB3 (0.46) TSHRPPARDHDAC8MEN1MAPT
SCHEMBL7753545 0.78 PRMT5 (0.44) PRMT5WDR77MEN1KMT2A
SCHEMBL5143830 0.78 PRMT5 (0.44) PRMT5WDR77MEN1KMT2A
SCHEMBL5142060 0.78 ADRB3 (0.48) PRMT5WDR77MEN1MAPTKMT2A
SCHEMBL5145473 0.77 PRMT5 (0.45) PRMT5WDR77TSHRMEN1MAPT
SCHEMBL7753292 0.77 PRMT5 (0.43) PRMT5WDR77TSHRMEN1MAPT
Hydrochloric Acid SCHEMBL7565474 0.77 ADRB3 (0.47) PRMT5WDR77TSHRMEN1MAPT
SCHEMBL5144158 0.77 PRMT5 (0.44) PRMT5WDR77TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217706-B2 Propanolamine derivatives ASTELLAS PHARMA INC. (JP) 2007-05-15 US disclosed
EP-1382333-A2 Use of beta 3 adrenergic receptor agonists in the treatment of dysuria FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-21 EP disclosed
US-6495546-B1 SUCH AS 1-(N-BENZYL-N-(3-METHOXY-6,7,8,9-TETRAHYDRO-5H-BENZO-CYCLOHEPTEN-6-YL)AMINO)-3-PHENOXY-2-PROPANOL; ADRENERGIC RECEPTOR AGONISTS; ANTIULCEROUS, LIPOLYTIC, ANTIURINARY INCONTINENCE AND ANTIPOLLAKIURIA ACTIVITIES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-12-17 US disclosed
US-20020120148-A1 Propanolamine derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-08-29 US disclosed
EP-1070046-A1 PROPANOLAMINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP disclosed
WO-1999051564-A1 PROPANOLAMINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120148-A1 Propanolamine derivatives AMY2A, PNMT, PNLIP CTSD 759/4885HTR1D 260/4885HTR1B 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.